Skip to main content
ESTA logo

ESTA · Establishment Labs Holdings Inc. · Financials

Track ESTA — free
$63.52 +1.24 (+1.99%) At close · Oct 22
Market Cap
$1.89B
Shares
29.80M
Volume · Oct 22 762.42K Avg daily vol (3M) 428.41K

Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.

Revenue
$211.08M +27.1%
FY2025 Revenue FY2017–FY2025
Net Income
-$51.06M +39.6%
FY2025 Net Income FY2017–FY2025
Gross Margin
69.32% +3.4pp
FY2025 Gross Margin FY2017–FY2025
Operating Margin
-18.48% +11.6pp
FY2025 Operating Margin FY2017–FY2025
Diluted EPS
-$1.72 +42.7%
FY2025 Diluted EPS FY2019–FY2025
Operating Cash Flow
-$50.89M +13%
FY2025 Operating Cash Flow FY2017–FY2025

Chart any reported metric, KPI or segment over time — the full statement history lives here

Line Item FY2026 (G) TTM FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019 FY2018 FY2017
$269M – $271M $245.82M $211.08MG $166.03MG $165.15MG $161.7MG $126.68MG $84.68MG $89.57M $61.21M $34.68M
— $72.54M $64.77M $56.5M $58.17M $55.11M $41.28M $32.17M $34.7M $25.09M $16.98M
— $173.27M $146.31M $109.53M $106.98M $106.6M $85.4M $52.5M $54.86M $36.12M $17.7M
— — 69.32% 65.97% 64.78% 65.92% 67.42% 62% 61.25% 59.01% 51.04%
— $20.33M $20.25M $19.71M $26.43M $20.27M $18.32M $13.79M $14.99M $12.69M $6.86M
— $171.7M $165.07M $139.81M $145.58M $125.98M $92.23M $66.63M $70.81M $47.3M $30.82M
— — $3.3M $2.1M $1.2M $1.2M $1.2M $900K $600K $600K $300K
— — $6.2M $4.7M $2.8M $2.5M $2.5M — — — —
— $192.03M $185.32M $159.51M $172M $146.25M $110.54M $80.42M $85.8M $59.98M $37.69M
— -$18.76M -$39.01M -$49.99M -$65.03M -$39.66M -$25.14M -$27.92M -$30.94M -$23.86M -$19.98M
— — -18.48% -30.11% -39.37% -24.53% -19.84% -32.97% -34.55% -38.99% -57.62%
— — -$32.81M -$45.29M -$62.23M -$37.16M -$22.64M — — — —
— $27.57M $25.26M $20.83M $15.39M $11.76M $9.06M $9.37M $8.7M $8.81M $10.42M
— $144K $423K $1.48M $1.02M $87K $23K $15K $4000 $16K $19K
— -$1.29M $5.82M -$15.29M $816K -$3.18M -$6.27M -$2.68M -$1.21M -$2.39M -$395K
— -$47.47M -$58.02M -$84.63M -$78.58M -$72.82M -$39.71M -$38.02M -$37.51M -$20.88M -$34.79M
— -$8.58M -$6.96M -$32K -$81K $2.39M $1.43M $104K $640K $215K $105K
— -$38.89M -$51.06M -$84.6M -$78.5M -$75.21M -$41.14M -$38.12M -$38.15M -$21.1M -$34.9M
— — -24.19% -50.95% -47.53% -46.51% -32.47% -45.02% -42.59% -34.47% -100.62%
— -$36.36M -$53.19M -$83.27M -$79.25M -$76.15M -$40.36M -$35.94M -$37.91M -$20.73M -$34.82M
USD/shares — -$1.29 -$1.72 -$3.00 -$3.07 -$3.08 -$1.72 -$1.63 -$1.86 — —
USD/shares — -$1.29 -$1.72 -$3.00 -$3.07 -$3.08 -$1.72 -$1.63 -$1.86 — —
shares — — 29.62M 28.16M 25.6M 24.46M 23.97M 23.32M 20.54M 17.35M 10.23M
shares — — 29.62M 28.16M 25.6M 24.46M 23.97M 23.32M 20.54M 17.35M 10.23M
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing. TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative. (G): the company's own guidance — a (G) column is a guided period not yet reported; a G marker shows how the reported figure landed against the guided range. Non-GAAP-basis guidance (*) is shown as stated and never judged against GAAP actuals.

Capital Returned to Shareholders

Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2017–FY2018: $4.51M in buybacks.

Debt Profile

Reported borrowing balances, repayment dates and agreement terms, with links to the underlying filings.

Reported debt balances

Each amount keeps its reported scope. Related balance-sheet measures appear under the borrowing they describe.

Reported balanceAs ofAmountSource
Noncurrent debt carrying amount 2026-06-30 USD 261,702,000 10-Q filed 2026-08-07
Noncurrent operating lease liabilities 2026-06-30 USD 1,972,000 10-Q filed 2026-08-07
Instrument and agreement coverage is incomplete. Additional filings are awaiting review.

Covenants

Covenant terms have not yet been verified for this profile.

The balance figures do not establish whether covenants apply or whether the company complies with them.

Loans, facilities and notes

The instrument breakdown is not yet verified. Read the debt note in the linked report for borrowing terms and maturity conditions.

Price & Valuation

Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.

Valuation

EV/Revenue
7.18×
Peer median 3.22×
EV/EBIT
—
Peer median 24.79×
P/E (TTM)
—
Peer median 27.06×

Peer medians compare against the 62 similar-size Medical Devices companies (of 156 listed).

Valuation over time computed as of each quarter's filing date

Revenue Breakdown

Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.

Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.

By Geography (USD)

Component FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019
EMEA $91,052,000 $78,209,000 $80,150,000 $62,419,000 $57,913,000 — —
North America $45,557,000 $4,410,000 $2,157,000 $995,000 $866,000 $511,000 $540,000
Latin America $39,926,000 $34,998,000 $48,891,000 $52,442,000 $38,226,000 $21,512,000 $27,994,000
Asia Pacific $34,541,000 $48,408,000 $33,953,000 $45,844,000 $29,677,000 — —
Asia Pacific and Middle East — — — — — $24,986,000 $24,819,000
Europe — — — — — $37,667,000 $36,212,000
Key facts CIK 1688757 CUSIP G31249108 13F (30d) 14 filings 14 filers Visit website Investor relations